Ratthanan Chantrakul

Ratthanan Chantrakul

Auto-generated profile, based on publicly available information

Ratthanan Chantrakul

Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine Prince of Songkla University Songkhla Thailand

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2025 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
TSTanat Saeoui
Tanat Saeoui
CKChayanis Kositamongkol
Chayanis Kositamongkol
RCRatthanan Chantrakul
Ratthanan Chantrakul
PSPimsiri Sripongpun
Pimsiri Sripongpun
NCNaichaya Chamroonkul
Naichaya Chamroonkul
Apichat KaewdechApichat Kaewdech
Apichat Kaewdech

22 December 2023 in Gastroenterology Report
Verified
Journal Article
Open access
PDF file
RCRatthanan Chantrakul
Ratthanan Chantrakul
PSPimsiri Sripongpun
Pimsiri Sripongpun
TPTanawat Pattarapuntakul
Tanawat Pattarapuntakul
NCNaichaya Chamroonkul
Naichaya Chamroonkul
CKChanon Kongkamol
Chanon Kongkamol
Apichat KaewdechApichat Kaewdech
Apichat Kaewdech
Chronic hepatitis B (CHB) significantly impacts the health-related quality of life (HRQoL), but remains underexplored in the Thai population. Health state utilities (HSU) are indicators reflecting HRQoL which serve as fundamental inputs for economic evaluation analyses. This study aimed at assessing differences in HRQoL across five CHB stages in Thai patients, including non-cirrhotic CHB, compensated cirrhosis, decompensated cirrhosis, early-/intermediate-stage hepatocellular carcinoma (HCC) and advanced-/terminal-stage HCC. We conducted a cross-sectional study to collect HRQoL data from patients with CHB at five stages. The study included patients with CHB who were followed up at a super-tertiary care centre between March 2021 and February 2022. The participants completed the EQ-5D-5L questionnaire and provided demographic data. Disease stage and relevant data were obtained from medical records. HSU and Euroqol-visual analogue scale (EQ-VAS) scores, calculated using Thai-specific conversion coefficients, were assessed. Among 422 patients, 236 did not have cirrhosis, 92 had compensated cirrhosis, 13 had decompensated cirrhosis, 55 had early-/intermediate-stage HCC, and 26 had advanced-/terminal-stage HCC. The HSU scores for non-cirrhotic, compensated cirrhosis, decompensated cirrhosis, early-/intermediate-stage HCC and advanced-/terminal-stage HCC were 0.95 ± 0.08, 0.89 ± 0.16, 0.79 ± 0.19, 0.89 ± 0.12 and 0.52 ± 0.39, respectively. Similarly, the EQ-VAS scores for various CHB stages were 83.56 ± 12.90, 80.48 ± 13.03, 68.76 ± 17.40, 79.00 ± 14.38 and 62.92 ± 20.62, respectively. A significant correlation (r = 0.469, P < 0.001) was observed between the HSU and EQ-VAS scores. The disease progression led to a notable HSU decline, particularly in the advanced-/terminal-stage HCC group (regression coefficient: –0.436, P < 0.001). The EQ-VAS scores indicated reduced quality of life in advanced liver disease. Later CHB stages compromise the HRQoL. Decompensated cirrhosis and advanced-/terminal-stage HCC profoundly affect physical health and quality of life, whereas patients with compensated cirrhosis and early-/intermediate-stage HCC report better HRQoL.